Skin Cancer Detection for Primary Care: Confident Clinical Assessment
In the fast-paced environment of family medicine, a “quick skin check” is often anything but simple. When a patient points out a suspicious mole during a routine visit, you are tasked with making a high-stakes triage decision in a matter of minutes.
Balancing the need to identify potential malignancies with the goal of avoiding unnecessary, invasive biopsies is a constant clinical challenge.
DermaSensor offers an objective primary care skin cancer detection solution that integrates into your daily workflow, providing data-backed support at the point of care.
Quick Facts About Skin Cancer Detection for Primary Care
96% Sensitivity
Demonstrated sensitivity for detecting all common skin cancers in pivotal clinical trials.
FDA-Cleared
The first automated, point-of-care device indicated for BCC, SCC, and melanoma.
Zero-Friction Workflow
Provides an objective "Monitor" or "Investigate" result in under 30 seconds.
Improved Outcomes
Use of the device resulted in a 30-52% relative reduction in missed skin cancers (false-negative referrals).
Clinician-Only
Available exclusively to healthcare professionals; not for consumer or home use.
Precision Support for the Skin Cancer Risk Evaluation for Physicians
DermaSensor serves as an adjunctive tool for healthcare providers to assist in evaluating skin lesions suggestive of the most common skin cancers. In practice, skin cancer risk assessment can involve managing a high volume of skin concerns with limited immediate access to specialized dermatology experts. This gap in seeing a specialist can lead to longer wait times as well as patient accessibility. According to the AAD, skin cancer is the most common cancer in the United States.
Despite this, the average wait time to see a dermatologist is approximately 36.5 days nationally, according to AMN Healthcare research, making point-of-care evaluation by a PCP a critical in the care pathway.
The device uses Elastic Scattering Spectroscopy (ESS) to assess cellular and sub-cellular features that are invisible to the naked eye. While it is not intended for the direct diagnosis of skin cancer, it provides objective information designed to inform your clinical decision-making. By adding spectral analysis to your visual exam, you can better determine if the skin lesion requires further clinical care.
Learn More about
Enhancing Diagnostic Certainty
Visual assessment alone is subjective, and in the primary care setting, diagnostic uncertainty can often lead to a higher rate of benign referrals. DermaSensor acts as an adjunctive tool to help narrow that uncertainty. The device result is determined using a proprietary machine-learning algorithm validated through clinical studies on thousands of diagnosed lesions. This objective “second look” aids management decisions by using clinical data rather than visual intuition alone.
Supporting Skin Checks in Routine Visits
Skin lesion concerns are rarely the primary reason for a primary care visit; they surface during routine physicals and annual wellness exams, DermaSensor is designed to be used in these clinical settings. Because it requires no gels, needles, or special site preparation, it can be introduced into a standard appointment. Patients in high-risk groups, including older adults, those with a history of significant sun exposure, and patients with Fitzpatrick skin types I and II can receive an objective point-of-care assessment without waiting weeks for a dermatology referral.
A Validated PCP Skin Lesion Assessment Tool
To be effective in a busy practice, a PCP skin-lesion assessment tool must be fast, reliable, and evidence-based. DermaSensor was built specifically to fit these clinical requirements.
The device is engineered to minimize disruption during a routine physical of a patient:
Requires no needles, gels, or special site preparation.
You take 5 quick recordings, and the device provides an automated result in seconds.
You can provide immediate, data-backed guidance to your patient before they leave the exam room.
Measurable Clinical Impact
The evidence for using AI-powered support in primary care is clear. Clinical trials showed*:
device sensitivity for detecting all skin cancers across Fitzpatrick skin types
PCPs correctly referred 91.4% of malignant lesions when aided by the device, compared to just 82.0% without it, a 52% reduction in missed cancer referrals (from 18.0% to 8.6%)
Reduce unnecessary referrals: can avoid 21-33%* of benign lesions that physicians biopsied and 61-77% of benign lesions of concern to patients, saving patients from expensive dermatology visits
of the study physicians agreed the device added value to their clinical care
agreed it would help detect more skin cancers
* Clinical evidence upon request
To request a full compendium of our published clinical studies and whitepapers
Refining Referrals and Managing Risk
Effective triage is about ensuring the right patients get to the right specialists at the right time. For the primary care physicians, this means distinguishing between high-risk malignancies and benign lesions that can be safely monitored.
Optimizing Specialist Utilization
When clinical uncertainty is high, the default is often a biopsy or referral. In studies, 50 physicians intended to biopsy or refer a high number of benign lesions due to visual ambiguity. DermaSensor helps refine these management decisions. In clinical trials, the device correctly classified 21-33%* of benign lesions that physicians had originally intended to biopsy. This allows you to focus your referral resources on the most critical cases and reduces "referral fatigue" among your local specialists.
Medicolegal and Clinical Reassurance
Utilizing an FDA-cleared, clinically validated tool provides a standardized layer of documentation for your practice. With a 98% negative predictive value (NPV) for melanoma, a "Monitor" result offers high reassurance that a lesion does not require immediate invasive intervention. This level of evidence-based support is invaluable for both risk management and patient communication.
Elevating the Standard of Patient Care
Patients increasingly expect their providers to utilize modern technology to improve their health outcomes. Integrating spectral analysis into your skin checks transforms a subjective exam into a precise, technological assessment.
Ready to integrate objective skin cancer detection into your clinical workflow?
See How It Works in Primary Care by booking a demo, or Contact Us to request a full clinical compendium and reimbursement guide.
FAQs about DermaSensor For Family Medicine
Skin Cancer Detection for Family Medicine - FAQs
How does DermaSensor complement dermatology expertise?
DermaSensor is a clinician-used decision support tool that complements, not replaces, dermatology expertise. It provides primary care physicians with an objective tool to triage more effectively, ensuring that dermatologists receive the most critical referrals while PCPs manage lower-risk cases with greater confidence.
What is the learning curve for this PCP skin lesion assessment tool?
The DermaSensor device is designed for immediate clinical use with minimal training. While no special certification is required, we provide comprehensive educational resources to ensure every skin cancer screening physician can effectively interpret results and integrate the device into their routine with no disruption to patient flow.
Is there reimbursement support available for clinicians for DermaSensor?
Yes, DermaSensor offers dedicated reimbursement support through our partnership with TRG (The Reimbursement Group). This includes assistance with documentation and guidance on integrating the device into your existing billing structure for both government and private insurance.
How does the DermaSensor device perform across different types of skin cancer?
DermaSensor is the first automated device indicated for BCC, SCC, and Melanoma. The algorithm was validated on a diverse database of over 20,000 scans, providing reliable accuracy across the most common malignant lesions encountered in primary care.
Can DermaSensor be used during a routine primary care visit?
Yes. The device is designed for point-of-care use during standard appointments, including annual wellness exams and routine physicals. It requires no special site preparation and delivers a result in under a minute, making it practical within typical appointment times.
Where can I find the clinical data supporting DermaSensor?
Detailed results from DermaSensor’s pivotal primary care trials and prospective studies are available on the website, including data on sensitivity, specificity, and missed cancer reduction. Contact DermaSensor to request the full clinical compendium.
Confidence Backed by Clinical Evidence
Request a demo to see how DermaSensor’s clinical performance translates to your patient evaluations.